Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 7, 2024
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Gabrielle M Gualtieri, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 28, 2022
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy IndividualsXiaoxing Wang, Martin E Dowty, Ann Wouters, et al.
Journal of Clinical Pharmacology|February 22, 2023
Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as ProbesXiaoxing Wang, Vivek Purohit, Martin E Dowty, et al.
Clinical and Translational Science|December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation StudyRavi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2006
Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonistsKenneth M Meyers, José Méndez-Andino, Anny-Odile Colson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 14, 2022
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in HumansJonathan N Bauman, Angela C Doran, Amanda King-Ahmad, et al.
Journal of Medicinal Chemistry|January 20, 2000
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffoldM Cheng, B De, N G Almstead, et al.
Pharmaceutical Research|August 10, 2023
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter ActivityYeamin Huh, Anna Plotka, Hua Wei, et al.
Scientific Reports|June 4, 2020
Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency DifferencesBrian S Gerstenberger, Mary Ellen Banker, James D Clark, et al.
The Journal of Allergy and Clinical Immunology|December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkersEmma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Pageof 6